Skip to main content
main-content

Medicine Matters branded image Welcome

We provide news, expert interviews, and educational resources to help you keep up with the latest developments in rheumatology

COVID-19: Lessons learned for rheumatology practice

Zachary Wallace

Zachary Wallace discusses the changes that have occurred in rheumatology practice as a result of the COVID-19 pandemic, and explores what lessons can be taken forward to improve patient care.

New additions to the Adis Journal Club – January update

Drugs & Therapy Perspectives

Browse January's selection of peer-reviewed articles from the Adis journal portfolio. Curated by the editors and updated monthly. These papers highlight topical research and reviews for the benefit of Medicine Matters readers.

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

IN FOCUS | Inflammatory arthritis

18-11-2021 | Rheumatoid arthritis | News

Excess mortality gap closing, but not for all rheumatic diseases

Individuals with rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis have almost comparable survival rates to those of the general population, Greek study findings indicate.

Common scores used in rheumatology

An at-a-glance reference guide to the scores that are commonly used in clinical trials & daily rheumatology practice

IN FOCUS | Gout and crystal arthropathies

06-11-2021 | ACR 2021 | Conference coverage | News

Data support serum urate-based treat-to-target approach in gout

Serum urate concentration is a valid surrogate endpoint for the reduction or absence of gout flares, suggest study findings presented at the ACR Convergence 2021 virtual meeting and published in The Lancet Rheumatology.

Febuxostat and cardiovascular risk in people with gout

How will the FAST trial results impact regulatory guidance & clinical practice?

IN FOCUS | JAK inhibitors

10-11-2021 | ACR 2021 | Conference coverage | News

ORAL Surveillance: Tofacitinib fails to show noninferiority vs TNF inhibitors for MACE, malignancy risk

The JAK inhibitor tofacitinib is associated with numerically higher rates of MACE and malignancy than TNF inhibitors in people with rheumatoid arthritis at high cardiovascular risk, show the ORAL Surveillance results.

JAK inhibitor safety

Data summary, expert discussion, & research news on the potential risks associated with JAK inhibitors.

IN FOCUS | Lupus

18-11-2021 | Rheumatoid arthritis | News

Excess mortality gap closing, but not for all rheumatic diseases

Individuals with rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis have almost comparable survival rates to those of the general population, Greek study findings indicate.

Anifrolumab for the treatment of lupus

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

IN FOCUS | COVID-19 & rheumatic disease

18-01-2022 | COVID-19 | Feature | Article

COVID-19: Lessons learned for rheumatology practice

Zachary Wallace discusses the changes that have occurred in rheumatology practice as a result of the COVID-19 pandemic, and explores what lessons can be taken forward to improve patient care.

COVID-19 vaccination in patients with rheumatic diseases

Get answers to key questions with recommendations from professional organizations

Stay informed with Medicine Matters

Get the latest developments in rheumatology delivered straight to your inbox

Podcasts

Interviews with expert rheumatologists on patient care

Image Credits